Flash Therapeutics Company
Flash is developing an oral compound to prevent AML relapse using novel findings linking HCK to AML. This small molecule will inhibit HCK and FLT3-ITD for the treatment of cancer. They have identified five potential compounds for further testing. One is moving on to IND filing while the other four are going to begin animal toxicology testing.
Industry:
BioTech
Technology:
Others
Last Funding Type:
Series A
Headquarters:
Boston, Massachusetts, United States
Founded Date:
2018
Funding Status:
Early Stage Venture
Total Funding:
5000000
Estimated Revenue:
$1M to $10M
Employee Number:
11-50